Webinars

APR 19, 2023 10:00 AM +08

The Evolving Landscape of Lung Cancer Treatment

Sponsored by: Thermo Fisher Scientific

C.E. Credits: P.A.C.E. CE ｜ Florida CE

Speaker

Abstract

1st Broadcast

April 18, 2023 | 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST)

2nd Broadcast

April 19, 2023 | 10:00am (SGT)

While a decade ago the prognosis of lung cancer patients was very disappointing, nowadays a substantial evolution is driven by targeted treatments and immuno-oncology. With extended, scaled genetic diagnostics—including qPCR, digital PCR, Sanger Sequencing, and NGS—becoming broadly available and aligned with evolving options of target treatment, outcome in metastatic nonsmall cell lung cancer (mNSCLC) is overriding a 50% survival proportion after 5 years in subgroups with gene-fusions (e.g., ALK-fusion). This is counterparted by the impact of immune checkpoint inhibition (ICI) with and without chemotherapy. Herein, mNSCLC with PD-L1-expression ≥ 50%, a 30% 5-year-survival probability is achieved and ICI is pushing borders over stages in patients with locoregional disease. Here, perioperative ICI implementation carries advancements in outcome and offers “window of opportunities” such as:

Strategies in the induction treatment scenario,
Even to delineate candidate biomarkers for further enrichment and patient stratification can be explored.

These parallel advancements of molecular diagnostic capabilities, targeted treatment options, and ICI development are driving the transition of the treatment landscape of lung cancer.

Learning points in this webinar will be:

Outline the total spectrum of evolving systemic treatment options in non-small cell lung cancer
Identify the impact of immunotherapy and molecular targeted treatments on patient outcome and the potential relevance of circulating tumor (ct)DNA assessment on guiding treatment
Discuss the integration of systemic treatment options in the multimodality setting of nonmetastatic locoregional disease

Webinars will be available for unlimited on-demand viewing after live event.

Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

The Evolving Landscape of Lung Cancer Treatment

Michael Thomas